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http://www.molecular-cancer.com/content/12/1/169RESEARCH Open AccessCD98hc (SLC3A2) drives integrin-dependent renal
cancer cell behavior
Marina Poettler1, Matthias Unseld1, Kira Braemswig1, Andrea Haitel2, Christoph C Zielinski1 and Gerald W Prager1*Abstract
Background: Overexpression of CD98hc (SLC3A2) occurs in a variety of cancers and is suspected to contribute to
tumor growth. CD98, a heterodimeric transmembrane protein, physically associates with certain integrin β subunit
cytoplasmic domains via its heavy chain, CD98hc. CD98hc regulates adhesion-induced intracellular signal transduction
via integrins, thereby, affecting cell proliferation and clonal expansion. Disruption of CD98hc led to embryonic lethality
in mice (E 3.5 and E 9.5) and CD98hc −/− embryonic stem cell transplantation failed to form teratomas, while CD98hc
over-expression in somatic cells resulted in anchorage-independent growth. However, it is unclear whether interference
with CD98hc expression tumor cell behavior.
Methods: Renal cell cancer cell lines have been used to determine the effect of CD98hc expression on cancer cell
behavior using cell adhesion, cell trans-migration and cell spreading assays. Flow cytometric analysis was performed to
study the rate of apoptosis after detachment or serum starvation. shRNA-lentiviral constructs were used to stably
knockdown or reconstitute full length or mutated CD98hc. The role of CD98 as a promotor of tumorigenesis was
evaluated using an in in vivo tumor transplantation animal model. Immunohistochemical analysis was performed to
analyze cell proliferation and CD98 expression in tumors.
Results: This report shows that CD98hc silencing in clear cell renal cancer cells reverts certain characteristics of
tumorigenesis, including cell spreading, migration, proliferation and survival in vitro, and tumor growth in vivo.
Acquisition of tumorigenic characteristics in clear cell renal cancer cells occurred through the integrin binding domain
of CD98hc. A CD98hc/integrin interaction was required for adhesion-induced sustained FAK phosphorylation and
activation of the major downstream signaling pathways PI3k/Akt and MEK/ERK, while overexpression of a constitutive
active form of FAK rescued the CD98hc deficiency.
Conclusions: In this study we demonstrate that loss of CD98hc blocks tumorigenic potential in renal cell cancer.
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Cytotoxic therapy is the only treatment available for many
malignant diseases. However, molecular target therapies
have recently become an additional and/or alternative
therapeutic option. Biologic treatment is thought to be
more specific, thereby resulting in fewer side effects. Renal
cell cancer is a prominent representative for the efficiency
of molecular target treatment, and led to the introduction
of bevacizumab, sorafinib, sunitinib, pazopanib, and axi-
tinib for the treatment of this disease [1-3].* Correspondence: gerald.pragergerald.prager@meduniwien.ac.at
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stated.Considering that not all patients respond to this kind of
treatment, and those who benefit may become resistant
[4,5], a better understanding of molecular mechanisms
involved in specific tumor cell behavior is a requisite for
efficient new therapeutic strategies. For example, the
determination of biomarkers such as protein expression
profiles might predict treatment response or prognosis.
In this context, we described the heavy chain of CD98
(CD98hc), a type II transmembrane protein, as a bio-
marker for less differentiated and more aggressive renal
cell cancers. We identified CD98hc as a marker of less dif-
ferentiated clear cell renal cell cancer (ccRCC, G2-4) as
well as of the less differentiated and more aggressive type
2 papillary renal cell cancer (pRCC). The benign renall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Under physiological conditions, CD98hc expression is
limited to proliferating cells and activated T cells. CD98hc
is mandatory for development, as genetic knock-out mice
are embryonically lethal between day E 3.5 and E 9.5 [7,8].
Moreover, CD98hc −/− embryonic stem cell transplan-
tation failed to form teratomas in mice [7]. In vitro in-
hibition of CD98hc led to reduced cell growth and the
induction of apoptosis in certain cell types, while overex-
pression of CD98hc in CHO cells resulted in anchorage-
independent growth [9].
A functional role of CD98hc has been described in so-
matic cells where the cytoplasmic tail of beta integrin
adhesion receptors was prerequisite for adhesion-induced
signal transduction and integrin-mediated cell behavior in
embryonic stem cells and fibroblasts [10-14]. In detail,
CD98hc binds to a highly conserved C-terminal domain
of integrin β1A and β3 cytoplasmic subunits, thereby af-
fecting the integrin signaling cascade. In contrast, CD98hc
does not interact with integrins β1D or β7 [12]. Fur-
thermore, clustering CD98hc activates multiple integrin-
dependent functions and mimics β1 integrin co-signaling
in T-cells. Although cell adhesion is dispensable for both
tumor cell- survival and -proliferation, mutation in beta
integrins disrupts tumorigenesis [15]. Furthermore, dele-
tion studies of integrins have demonstrated that the ex-
tracellular domain of integrins is dispensable, while the
cytoplasmic domain is essential for tumor growth [15-17].
This is consistent with our previous findings that CD98hc
directly interacts with the cytoplasmic domain of β1 or β3
tails [18]. The light chain of CD98 reconciles amino acid
transport activity [19] and is covalently linked via disulfide
bridges to CD98hc. The heavy chain is thereby essential to
traffic the CD98 light chains to the cytoplasmic mem-
brane [20].
Based on our recent data, we hypothesized that high
expression of CD98hc influences malignant tumor cell be-
havior. We identified that CD98hc mediates tumor trans-
plant growth in vivo. Utilizing both, gain and loss of
function experiments in vitro, we also found that CD98hc
is a major regulator of tumor cell behavior, thereby affec-
ting tumor cell migration, proliferation, spreading and sur-
vival in vitro. The integrin-interacting domain of CD98hc
was thereby crucial as truncation mutants were incapable
to rescue CD98hc deficiency. Our data provides the first
evidence that a biomarker, which is consistently over-
expressed in high malignant renal cell cancers, bears a
central functional role in integrin-dependent signal trans-
duction and tumor cell behavior.
Results
CD98hc expression affects RCC growth in vivo
Previously, we observed a direct correlation between
CD98hc expression in clear cell renal cell cancer (ccRCC)and grade of differentiation [6]: We now analyzed CD98hc
expression in paraffin-embedded tumor tissue sections de-
rived from 51 ccRCC patients: The aggressive and less dif-
ferentiated G3 and G4 ccRCC tumors were characterized
by high CD98hc (G3: 87.0%; G4: 100.0%) expression, while
the more differentiated G1 ccRCC revealed no CD98hc
expression (G1: 0.0%). G2 had infrequent CD98hc ex-
pression (64.7%) (Figure 1A). [Qui square test: p = 0.007,
n = 51]. Beside tumor cells, endothelial cells and lympho-
cytes revealed a positive immunostaining for anti-CD98hc.
Although CD98hc has been suggested to affect cell beha-
vior of somatic cells such as vascular smooth muscle cells
[21], keratinocytes [22] or embryonic stem cells [7] most
likely via integrins [18], any regulatory role of CD98hc is
renal cell cancer cells has hitherto been unknown.
Thus, we generated a stable low CD98hc expressing
ccRCC cell line (lowCD98hc/CaKi2) as well as a control
high CD98hc expressing ccRCC cell line (highCD98hc/
CaKi2) by the use of a CD98hc mRNA targeting shRNA
and scrambled control bearing lentiviral construct, re-
spectively. A PLKO-puro1 construct, lentiviral infection
of CaKi2 cells led to stable downregulation of CD98hc
to 5 ± 2% of highCD98hc/Caki2. When each stable cell
lines were transplanted into athymic nude mice, a sig-
nificantly enhanced tumor growth was only observed in
the CD98hc over-expressing tumor transplants on day 8
(135 ± 21 mg in highCD98hc/Caki2 vs. 12 ± 9 mg in
lowC98hc/Caki2 tumors, n = 5 mice/group) (Figure 1B).
This was reflected by the enhanced immunoreactivity of
an antibody against the proliferating cell nuclear antigen
(PCNA), which represents a proliferation marker, in the
highCD98hc expressing tumors cells, while the immuno-
reactivity in the lowCD98hc/CaKi2 transplants was faint
(Figure 1C).
Regulation of CD98hc expression in clear cell renal cancer
cells
Having shown that expression of CD98hc expression is
accompanied by tumor growth, we aimed to analyze
causal underlying subcellular mechanisms. Various siRNA
constructs were synthesized and applied in established
renal cell cancer cell lines, such as CaKi1, CaKi2 or A-498
[20]. Although highest transfection efficacy was obtained
in CaKi2 cells, key experiments revealed consistent results
in all cancer cell lines used.
CD98hc is a known interaction partner of integrin beta
1 and beta 3 subunits. However, regulation of CD98hc ex-
pression was not affected by integrin engagement, because
in Caki2 cells seeded on the β1/β3 integrin ligand fibro-
nectin as well as the artificial non-integrin ligand poly-
D-lysine CD98hc was efficiently downregulated via siRNA
(Figure 2A). Importantly, integrin β1/β3 expression were
not affected by CD98hc regulation as were their ligand
binding activity not altered. WOW-1 immunoreactivity, a
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Figure 2 CD98hc expression is not affected by integrins. (A) Western blot (under reducing conditions). Matrix independent CD98hc
expression, 85 kDa. Loading control = beta actin, 45 kDa. FN = cells seeded on fibronectin for or PDL (poly – D – lysine). Representative blots are
demonstrated. 4 separate experiments. (B) FACS analysis demonstrate no alteration in beta 1 (upper pattern) or beta 3 (lower pattern) integrin


































Figure 1 CD98hc expression is correlated with grading of clear cell renal cell cancer (ccRCC) and affects tumor growth in vivo.
(A) Immunohistochemical staining for CD98hc in clear cell renal cell cancer. Left: high CD98hc expressing grade 4 ccRCC; right: no immunoreactivity
of the anti-CD98hc mAB in grade 1 ccRCC. (B) In vivo tumor transplantation assays: Tumor weight (mg), lowCD98hc/Caki2 tumors, highCD98hc/Caki2
tumors. (* p< 0.0001, data represent mean ± S.D. of five mice per group after 8 days) (C) CD98hc expression was analyzed via immunofluorescence
staining of low and highCD98hc/Caki2 cell tumors, grown for 8 days in the right flank of nude mice. Upper left: anti CD98hc in low CD98hc/Caki2
tumors, lower left: anti - PCNA staining in lowCD98hc/Caki2 tumors, upper right: anti C98hc in highCD98hc/Caki2 tumors, lower right: anti – PCNA in
high CD98hc/Caki2 tumors. Size bars 200 μm.
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rin αvβ3, was not affected (lowCD98hc/Caki2 = 70 ± 3% of
control, highCD98hc/Caki2 = 67 ± 8% of control, p = 0.12,
n = 3).
CD98hc regulates integrin-dependent cell functions in
ccRCC
As CD98hc is whether affecting neither integrin ex-
pression (Figure 2B) nor its ligand binding capacities (see
above), it was expected that regulation of CD98hc expres-
sion had no effect on Caki2 cell adhesion towards the in-
tegrin -β1/-β3 matrix protein fibronectin (Figure 3A).
While it was previously reported that CD98hc does not
affect integrin activation (inside-out) (Feral 2005), there isA B 
D E
Figure 3 Down-regulation of CD98hc results in reduced migration, pr
highCD98hc/Caki2 cells were seeded for 10, 20, 40 and 60 min on 10 μg/m
field with 20x magnification (n= 3, data represent the mean ± SEM, p=0.753),
fibronectin spreading was measured after 10, 20, 40 and 60 min. n=3, data re
transmigration was analyzed using a modified Boyden chamber system, whic
(white bars: mean 20 ± 3 cells/field after four hours, mean 122 ± 46 cells/field
highCD98hc/Caki2 cells (black bars: mean 103 ± 5 cells/field after four hours,
(D) Cell proliferation: cell [3 H] thymidine incorporation was reduced to 52 ± 3
lowCD98hc/Caki2 cells when compared to control (highCD98hc/Caki2). n = 3
induced by serum starvation or anoikis was measured via Annexin V/PI – FAC
to apoptosis. Upper left panels point out necrotic cells. Representative dot bloincreasing evidence that CD98hc is a major mediator
of adhesion-induced intracellular signal transduction via
integrins (outside-in) [7,18]. Thus, we next analyzed po-
tential effects of CD98hc in integrin-specific cell behavior
in ccRCC cells.
LowCD98hc/Caki2 cells had an impaired cell spreading
behavior when seeded on the integrin -β1/-β3 matrix
fibronectin (Figure 3B), an effect which engages integrin-
induced Rac and CDC42 activation [23]. Furthermore,
ccRCC cell transmigration was affected by CD98hc ex-
pression, because the 4 hours transmigration rate of
lowCD98hc/CaKi2 cells was decreased to 19 ± 2%, 24 ± 7%
after 12 hours and 41 ± 4% after 24 hours when compared
to highCD98hc/Caki2 cells (Figure 3C).C
oliferation and survival in Caki2 cells. (A) Cell adhesion: Low and
l fibronectin and stained with crystal violet. Cells were counted per
(1 field = 0.5 mm2). (B) Cell spreading: After attachments to 10 μg/ml
present the mean ± SEM, *p<0.001 (C) Cell transmigration: cell
h revealed diminished migratory capability in lowCD98hc/Caki2 cells
after 12 h and 520 ± 67 cells/field after 24 h) when compared to
mean 495 ± 89 cells/field after 12 h and 1257 ± 346 cells/field 0.5 mm²)
% after 24 h incubation under normal medium conditions in
, data represent the mean ± SEM, * p < 0.001. (E) Cell survival: Apoptosis
S analysis, which revealed that lowCD98hc/Caki2 cells were more prone
ts given; n=5.
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propagation. As the in vivo tumor proliferation analysis
(Figure 1C) suggested a proliferation dependency on
CD98hc expression, we were next interested in a potential
regulation of CD98hc in ccRCC cell proliferation in vitro.
By a 3H-thymidin incorporation assay a reduction to
52 ± 3% after 24 h was observed in lowCD98hc/Caki2
(Figure 3D). A prerequisite of metastasis formation is
adhesion independent cell survival (anti- anoikis) as well
as survival upon serum-starvation. High CD98hc/Caki2
cells were characterized by sustained cell survival, while
low CD98hc expressing Caki2 cells were more prone to
anoikis or apoptosis (Figure 3E).
From these data we conclude that CD98hc expression
is essential for malignant ccRCC behavior including cell
spreading, cell migration, cell proliferation and cell survival.A
C
Figure 4 The cytoplasmic domain of CD98hc is responsible for malign
binding was performed utilizing a QuickChange Kit (Stratagene) for the sile
used to interfere with the integrin interaction (TrunSilCD98hc in B) and po
transporter interaction (poinsilCD98hc in C). Constructs were cloned in pcD
transmembrane domain, CPD: cytoplasmic domain). (B) Tumor weight (in m
Caki2 tumors, trunsilCD98hc/Caki2 tumors, poinsilCD98hc/Caki2 tumors. * p
(C) CD98hc expression was analyzed via immunofluorescence staining of lo
Caki2 cell tumor transplants, grown for 8 days after injection into the right
panel indicate anti - PCNA staining.The cytoplasmic domain of CD98hc is responsible for
malignant tumor growth in vivo
To further elucidate whether interaction of CD98hc with
the amino acid transporter (light chains of CD98), which
engages the extracellular domain of CD98hc, or inter-
action with integrin adhesion receptors, which engages the
cytoplasmic domain of CD98hc, we introduced CD98hc
reconstitution mutants: (i) first, a silent mutation escaping
shRNA binding capacities, thus, reconstituting for wild
type CD98hc (silCD98hc) (ii) a silent mutation plus a trun-
cation mutant lacking the cytoplasmic domain of CD98hc
(trunsilCD98hc), which is expected not to interact with
integrins [7] (iii) a silent mutation plus exchange muta-
tions of the cysteins, thus, lacking CD98hc interaction with
its light chains (poinsilCD98hc) (Figure 4A). Equally ex-
pression of silent mutations was confirmed by FACSB
ant tumor growth in vivo. Reconstitution of CD98hc omitting shRNA
nt mutation (silCD98hc in A); a cytoplasmic truncation mutant was
int mutations in Cys109 and Cys330 interfered with amino acid
NA 3.1 Vector via ECO RI. (ECD: extracellular domain, TMD:
g), highCD98hc/Caki2 tumors, silCD98hcCaki2 tumors, lowCD98hc/
< 0.0001. Data represent means ± S.D. of three mice per group.
wCD98hc, highCD98hc, silCD98hc, trunsilCD98hc and poinsilCD98hc
flank of nude mice. Upper panel indicate anti CD98hc staining, lower
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were not affected by these mutations (data not shown).
By stable expressing these mutants in lowCD98hc/CaKi2
cells, we tested the functional role of CD98hc in vivo using
tumor transplant assays. Reconstitution of wild type CD98hc
in lowCD98hc/Caki2 by silCD98hc led to a similar rate in
tumor growth as compared to highCD98hc/Caki2.
The single point mutations, lacking interaction with
the amino acid transporters, only partly reconstituted for
tumor growth, while the reconstitution with the trunca-
tion mutant lacking integrin interaction (trunsilCD98hc)
failed to improve the tumor growth rate (Figure 4B).
Time-dependent tumor growth was consistently accom-
panied with immunoreactivity of an anti-PCNA antibody
binding, reflecting cell proliferation in vivo (Figure 4C).








Figure 5 Reconstitution of CD98hc rescues the rates of migration, pro
adhesion in reconstitution mutant expressing CaKi2 cells: Adhesion was slig
silCD98hc expression or poinsilCD98hc expression showed no relevant corr
p > 0.05). (B) Spreading: Reconstitution with silCD98hc rescued the low CD
deletion mutant trunsilCD98hc Caki2 cells could not rescue reduced spread
lowCD98hc/Caki2 cells. poinsilCD98hc/Caki2 cells had a similar rescued spr
represent the mean ± SEM, * p < 0.001 (C) Transmigration of cells expressi
chamber system revealed diminished migratory capability in trunsilCD98hc
Caki2 cells (mean 100 ± 7 cells/field after 4 h) as well as to poinsilCD98hc C
* p < 0.001 (D) Cell proliferation in reconstitution mutants: Reconstitution o
CD98hc expressing cells. trunsilCD98hc/Caki2 cells had similar proliferative
cells could partially reconstitute for cell proliferation, however, the lower pr
significant. n = 4, mean ± SEM, * p < 0.001, # > 0.05 (E) Survival in reconst
V/PI– FACS analysis. Upper left panels reflect necrotic cells. Upper left paneefficient in vivo tumor growth, whereby the cytoplasmic
domain of CD98hc, which is thought to interact with in-
tegrin cytoplasmic domains thereby mediating adhesion
induced signaling transduction is essential, while inter-
action with the CD98 amino acid transporter only partly
contributed to efficient tumor growth.
The cytoplasmic domain of CD98hc is essential for
integrin-induced ccRCC cell behavior
Next, the respective mutations were stably expressed in
the low CD98hc ccRCC cell line CaKi2 using a retrovirus
(pBABE). Stable cell lines were analyzed for cell adhesion
properties on the integrin -β1/-β3 ligand fibronectin.
Neither high nor low CD98hc Caki2 nor the mutant
expressing Caki2 cell lines revealed significantly altered







liferation and survival in low CD98hc CaKi2 cells. (A) Cell
htly, but not significant reduced in trunsilCD98hc Caki2 cells.
elation in cell adhesion. (n = 4, data represent the mean ± SEM,
98hc cell spreading phenotype starting after 20 min. However, the
ing at any time point, but had a similar spreading behavior as
eading effect as silCD98hc reconstitution in Caki2 cells. n = 3, data
ng reconstitution mutants: Transmigration in a modified Boyden
/Caki2 cells (mean 13 ± 2 cells/field after 4 h), compared to silCD98hc
aki2 cells (mean 99 ± 3 cells/field after 4 h). n = 3, mean ± SEM,
f silCD98hc was able to rescue the proliferative phenotype of low
activity such as lowCD98hc/Caki2 cells, whereas poinsilCD98hc/Caki2
oliferative activity compared to highCD98hc/Caki2 was statistical not
itution mutant expressing cells: Apoptosis assay measured via Annexin
ls reveal necrotic cells. Representative dot blots given; n=3.
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dependent cell spreading, we found that the low as well as
the trunsilCD98hc Caki2 cells had a diminished spreading
behavior. TrunsilCD98hc expression in Caki2 cells, which
lack CD98hc interaction with the integrin β tails, could
not rescue the integrin specific cell spreading behavior of
lowCD98hc/Caki2. In contrast, poinsilCD98hc Caki2 cells
had a similar spreading behavior as highCD98hc/Caki2
cells or silCD98hc/Caki2 cells (Figure 4B). Consistently,
other integrin-induced cell behavior properties such as
transmigration of CaKi2 cells were also dependent on the
N – terminal domain of CD98hc, because trunsilCD98hc
Caki2 cells could not reconstitute the high CD98hc
phenotype (Figure 4C).
By studding either highCD98hc/Caki2 cells, lowCD98hc/
Caki2 cells, silCD98hc/Caki2 cells, trunsilCD98hc/Caki2 or
poinsilCD98hc/Caki2 cells for tumor cell proliferation,
we found that only the wild-type CD98hc reconstituting
mutant silCD98hc could completely rescue the high pro-
liferative phenotype (93 ± 4% after 24 h and 98 ± 2% after
48 h of high CD98hc Caki2, p < 0.001). In contrast, the
truncation mutant bearing cells (trunsilCD98hc/Caki2)
had a similar proliferation character as lowCD98hc/Caki2
cells (trunsilCD98hc 49 ± 1% after 24 h and 53 ± 2% after
48 h of silCD98hc; lowCD98hc/Caki2 cells with 38 ± 3%
after 24 h and 49 ± 5% of highCD98hc Caki2 cells after
48 h, p < 0.001 (24 h) and p < 0.001 (48 h)). The poin-
silCD98hc/Caki2 cells, however, had a non-significant
(p = 0.75) trend for a diminished proliferative activity
when compared to highCD98hc/CaKi cells (77 ± 2% of
silCD98hc after 24 h and 86 ± 4% of silCD98hc after 48 h).
The cytoplasmic domain of CD98hc might thus play a
major role in renal cancer cell proliferation most likely via
previously described interaction with integrin β tails [12]
(Figure 5D).
Finally, we tested the mutants for cell survival upon
starvation as well as upon cell detachment. Thus, we
found that silCD98hc as well as poinsilCD98hc could re-
constitute for high CD98hc expression, while the trunca-
tion mutant trunsilCD98hc showed a similar apoptosis
behavior as the low CD98hc Caki2 cells (Figure 5E).
From these data we conclude that the cytoplasmic do-
main of CD98hc is essential for mediating tumor cell
function as it affects cell spreading, cell transmigration,
cell proliferation and cell survival.
Cytoplasmic domain of CD98hc is responsible for
integrin-induced signal transduction and cell spreading
Adhesion-dependent FAK activation leads to induction
of downstream signaling pathways such as MEK/ERK, a
major driver pathway for cell proliferation, or PI3K/Akt,
a major cell survival and motility inducer. Thus, we next
analyzed whether the previously suggested cytoplasmic
domain of CD98hc is also responsible for adhesion-induced signal transduction in the cancer cell line CaKi2.
We found, that silCD98hc as well as poinsilCD98hc could
rescue adhesion-induced Y576 FAK phosphorylation,
while the low CD98hc as well as trunsilCD98hc mutants
did not lead to an increase in phosphorylation of FAK
Y567. Consistently, major downstream signaling pathways
such as PI3kinase/Akt as well as MEK/ERK were only
activated upon cell adhesion on fibronectin whenever the
cytoplasmic domain of CD98hc was present. This effect
was independent of the cysteine sides described for light
chain interaction (Figure 6A).
To analyze whether integrin-induced signal transduc-
tion is indeed responsible for CD98hc-dpendent tumor
cell behavior, we next overexpressed dominant active
FAK. Integrin-induced FAK phosphorylation was shown
to be dependent on the direct interaction of CD98hc with
a conserved domain of the cytoplasmic tail of beta-1
integrins [18], thus overexpression of active FAK is
thought of rescue CD98hc deficiency. highCD98hc/Caki2
or low highCD98hc/Caki2 were transiently transfected
with dominant active FAK or empty vector. While with
the control vector transfected lowCD98hc/Caki2 cells had
a significant reduced spreading phenotype when com-
pared to the control vector infected highCD98hc/CaKi2
cells, active FAK was capable to rescue for CD98hc defi-
ciency. These data suggest FAK as a downstream effector
of CD98hc in tumor cell behavior (Figure 6B).
Discussion
Recent advances in our understanding of the complex
molecular mechanism for malignant transformation,
tumor growth, and propagation have led to a much more
complex set of challenges for diagnostic or therapeutic
strategies than originally anticipated. Among the drivers
of malignant growth, receptor tyrosine kinases, functional
activating molecular mutations, as well as integrin adhe-
sion receptors are thought to be the major contributors of
tumorigenesis. In this context the integrin-interacting
molecule CD98hc, a type II transmembrane glycoprotein,
was demonstrated to lead to malignant transformation,
whereby CD98hc acted as an oncogene stimulating mo-
lecule leading to anchorage– independent growth within
CHO cells [9].
Further evidence of the pivotal role of CD98hc in malig-
nant growth was provided by an embryonic stem (ES) cell
transplantation model, whereby only wild type CD98hc
expressing embryonic stem cells formed teratomas, while
CD98hc deficient embryonic stem cells showed a signifi-
cant reduction in proliferation as well as reduced cell sur-
vival characteristics, thereby leading to diminished tumor
growth [7]. We recently demonstrated that CD98hc ex-
pression is mainly found in the less differentiated and
more aggressive renal cell cancer subtypes such as type II
papillary renal cell cancer or clear cell renal cell cancer
highCD98hc silCD98hc lowCD98hc trunsilCD98hc poinsilCD98hc
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Figure 6 The cytoplasmic domain of CD98hc regulates integrin-induced signal transduction and spreading. (A) Signaling: CD98hc is a
major contributor to integrin-dependent signal transduction involving pFAK, Akt as well as the MEK/ERK pathways. High and low CD98hc Caki2
cells as well as the mutated Caki2 cells silCD98hc/Caki2, trunsilCD98hc/Caki2 and poinsilCD98hc/Caki2 were permitted to adhere to fibronectin
for time-spans indicated. Phosphorylation of FAK (lane 1) was compared to total FAK (lane 2) as well as phosphorylation of pSer Akt (lane 3) was
compared to total Akt (lane 4). Furthermore, phosphorylation of p44/42 MEK/ERK (lane 5) was compared to total p44/42 (lane 6). Only the
trunsilCD98hc Caki2 cells were unable to rescue the lowCD98hc/Caki2 effect on intracellular signal transduction. n = 3, data represent the
mean ± SEM, * p < 0.001 (B) Cell spreading assays: highCD98hc/Caki2 and lowCD98hc/Caki2 cells were either transfected with dominant active FAK
of the empty control vector. Cells were seeded on fibronectin (FN, 10 μg/ml) for indicated time spans before cell area was assessed. Bars indicate
SEM- standard error of mean.
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patients demonstrated a significant correlation between
CD98hc expression and grade of malignancy (Figure 1A).
Based on these and previous observations, we hypothe-
sized that CD98hc is a major driver of malignant tumor
cell behavior and aimed to characterize any pivotal func-
tional role of CD98hc in tumor cell biology. Thus, we first
generated either high expressing CD98hc or very low
CD98hc expressing ccRCC cell lines to analyze malignant
cell behavior as well as the molecular pathways respon-
sible for CD98hc mediated tumor cell functions.
In order to test whether CD98hc plays a role within renal
cell carcinoma biology, we xeno-transplanted highCD98hc/
Caki2 cells or lowCD98hc/Caki2 cells into nude mice.
We observed a striking difference in tumor growth andsubsequent loss of anti-PCNA immunoreactivity. This
suggested that CD98hc regulates tumor cell proliferation
(Figure 1B). Moreover, we were able to exclude any effect
of CD98hc on integrin expression or integrin-ligand bin-
ding capacities (Figure 2B, Figure 3A). This is consistent
with previous observations that CD98hc does not affect
integrin expression or activation [7], but mediates adhe-
sion-induced signal transduction (outside-in signaling).
This is most likely induced by direct interaction of the
cytoplasmic domain of CD98hc with a conserved motif of
the C-terminal end of integrin beta-tails, which is a prere-
quisite for efficient FAK phosphorylation upon cell adhe-
sion [18]. Although not proven, it is tempting to speculate
that CD98hc might promote complex formation of most
upstream signaling molecules such as member of the
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whether CD98hc-dependent tumor growth in vivo was
mediated via integrin-induced signal transduction (outside-
in) or CD98hc-dependent amino acid transportation via its
light chains. When we first examined integrin-mediated
cell behavior, such as cell spreading, cell migration or
anoikis, the so called apoptosis upon cell detachment, we
found that all these cell functions were dependent on
CD98hc-expression. This was an important observation as
it was unclear whether these tumor cell functions were
affected by CD98hc. Our data suggest that CD98hc, when
over-expressed, augments malignant cell behavior, such as
tumor cell spreading, transmigration, proliferation, or
cell survival. All these functions are thought to be hall-
marks for circulating tumor cell survival and metastasis
formation.
Although integrin-dependent cell functions were strongly
affected by CD98hc expression, were still interested
whether the cytoplasmic integrin-interaction domain
[9,18] or the cysteine-bridges to the amino-acid transpor-
ting light chains of CD98hc were dispensable for malig-
nant tumor cell behavior. We generated silent mutations,
which were not recognized by shRNA constructs, in order
to rescue CD98hc expression in lowCD98hc ccRCC cells.
We also introduced either cytoplasmic domain-truncation
mutants (trunsilCD98hc) or mutants which lack the light
chain interaction (poinsilCD98hc). We found that the
major steps of malignant cell behavior were dependent on
the cytoplasmic tail of CD98hc, among them tumor cell
migration, cell spreading, cell proliferation as well as
cell survival. In contrast, the amino acid transport ac-
tivity partly affected cancer cell proliferation in vitro and
in vivo, which was not statistically significant (p-value high
CD98hc vs. poinsilCD98hc p = 0.12). Finally, our in vitro
findings were also reflected by in vivo tumor transplan-
tation assays (Figure 4).
One could speculate that the interaction partners for
CD98hc beta 1 integrins as well as beta 3 integrins, which
are both expressed in CaKi2 cells and have previously
been shown to interact with CD98hc [9,10], were media-
ting adhesion-induced signal transduction via induction of
FAK and c-src whenever CD98hc was present. This is also
supported by the fact that whenever the cytoplasmic do-
main of CD98hc for integrin binding was absent, for
instance in CD98hc reconstituted cells, a diminished FAK
phosphorylation upon cell adhesion on a beta 1 integrin
as well as beta 3 integrin-specific matrix protein was
observed.
Furthermore, overexpression of dominant active FAK
rescued the low CD98hc spreading phenotype. This is of
special importance in respect to previous findings that
malignancy of certain tumor cells depends on activation
of upstream integrin signaling events [11]. This is also
consistent with our in vivo findings that the absence ofthe cytoplasmic domain of CD98hc, which was demon-
strated to be responsible for efficient integrin-induced
signal transduction [10], led to a significant reduction in
tumor growth. In a previous study, we analyzed CD98hc
expression in various tumor cell lines and found that
CD98hc is frequently expressed in aggressive tumor cells
derived from adenocarcinomas of the lung, colon and
breast [6]. Therefore, CD98hc expression is significantly
associated with more aggressive and less differentiated
G3, G4 ccRCC (Figure 1A) and supports the observation
of an enhanced activation state within tumor cells.
Whether ccRCC metastasis formation generally depends
on CD98hc expression was not the focus of this study
and is currently being investigated.
Conclusion
In conclusion, by a combination of different in vitro and
in vivo attempts, we aimed to define a potential functional
role of CD98hc in renal cell cancer. We observed a cor-
relation between less differentiated and more aggressive
clear cell renal cell cancer and CD98hc expression. We
found that CD98hc is not only a descriptive marker for
aggressive cancers, but bears a major regulatory role of
malignant cell function. This was demonstrated by knock
down and reconstitution in vivo and in vitro, thereby sug-
gesting that the integrin interacting domain of CD98hc is
required for the malignant phenotype of renal cancer cells.
It is tempting to speculate, that these novel insights will
lead to more effective strategies in cancer treatment.Methods
Cell culture
Caki-2 cells were cultured in RPMI 1640 (10% FBS and 5%
Penicillin/Streptomycin). 24 hours prior to experiments
cells were maintained in antibiotic free medium under
serum reduced conditions (5% FBS). Experiments were
performed under serum-free conditions.Downregulation of CD98hc and production of lentiviral
particles
CD98hc siRNA was purchased from Santa Cruz-
Biotechnology and used according to manufactures in-
structions. Primers for shRNA CD98hc were purchased
from Invitrogen. Annealed oligos were cloned AgeI/
EcoRI to pLKO-puro1. pLKO.1 TRC Cloning Vector
and reagents were used from Addgene and carried out
according to the manufactures guidelines. Cells were
coated on polyprene (10 μg/ml) prior to lentiviral appli-
cation, medium was changed after 24 hours and protein
quantification was performed after 48 hour. For ge-
neration of stable lowCD98hc or highCD98hc/Caki2
(scrambled shRNA) cells were grown in the presence of
puromycin (5 μg/ml) for at least two weeks.
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Reconstitution of CD98hc by silent mutations was per-
formed utilizing a QuickChange-Kit (Stratagene) using a
pcDNA 3.1 Vector. The cytoplasmic truncation mutant
(trunsilCD98hc), the deltaWALLL truncation nucleotide
1–87, has been described before [9] and was generated
to interfere with integrin interaction. The Cys109 and
Cys330 (poinsilCD98hc) were performed as described by
Fenczik, 2001 [20]. Constructs were cloned in pBABE
via ECO-RI [20,24]. All numbering uses the amino acid
sequence reported in entry 4F2_human (P08195-1) of
the Swiss-Prot data base as of January, 2010.
Transient transfection of HEK-293 cells and retroviral
infection of lowCD98hc Caki2 cells were performed as
described before [25]. Stable infectants were selected in
growth medium containing 1 mg/ml puromycin.
Proliferation assays
MTT-test
50 μl normal medium was transferred in 96-well plate and
incubated at 37°C. Cells were harvested with Trypsin/
EDTA and cell number was counted. 5000cells/well were
transferred in 96-wells and incubated for 24 or 48 hours.
15 μl Dye solution was then added and again incubated
4 hours. 100 μl Solubilisation-/Stop-solution was added
and after 2 hours at room temperature absorption was
measured in a photometer at 750 nm.
Counting – assay
Cells were harvested with trypsin/EDTA as described
above; 1000, 2000 or 5000 cells were transferred in each
plate (96well) before cells of 10 fields of a raster ocular
(1 field = 1 mm2) were counted under light microscope
after one hour adhesion time and counted again after 24
and 48 hours.
Thymidine incorporation
Different concentrations of lowCD98hc/Caki2 cells or
control cells were seeded in a 96well plate with medium
(RPMI + 10% FCS + 1% P/S). After 18 h cells were
treated with 50 μl per well thymidine (H3 : RPMI = 1:10)
1 h, 37°C, 5%CO2 before cells were washed and lysed.
Incorporated 3H-thymidine was then detected by liquid
scintillation.
Cell transmigration
Cell migration was assayed in a modified Boyden
chamber-system by using transwell membranes (8 μm)
coated with 1% gelatin. Cells were seeded on the top of
the membrane in medium without FCS, while in the lower
chamber 10% FCS was added as a stimulus. After four
hours filters were washes with PBS ×1, fixed (Methanol:
acetic acid, 3 : 1) and nuclear stained with DAPI. Migrated
cells in the lower chamber were counted using an AX70Olympus-microscope and compared to controls (absolute
numbers per mm2 is given).
Cell survival
Anoikis- and starvation-assays
Poly 2-hydroxyethyl-methacrylate (polyHEMA) was used
for detachment cell survival assays. PolyHEMA was
diluted in 75% ethanol as described by manufacture,
mixed and kept at 37°C overnight. One hour before ex-
perimental onset 110 μl of PolyHEMA was added in 24-
well plates and air dried at room temperature. 1×106
cells were then transferred in prepared 24- well plates
and after 24 or 48 hours incubation time apoptosis upon
detachment was measured. For cell starvation, 1% BSA
for 24 or 48 hours at 37°C, 5%CO2 was used.
Cells were stained with Annexin V-FITC Detection Kit
(Alexis Biochemicals, Farmingdale, NY) and propidium
iodide to estimate apoptosis and necrosis via flow cyto-
metry (FACSCalibur, BD).
Cell adhesion and spreading
Assays of cell spreading were either performed on 20 μg/
ml fibrinogen (Fg) or 10 μg/ml fibronectin (FN) or 10 μg/
ml Poly-D-Lysine (Millipore) as described previously [26].
The cells were allowed to attach for 30 minutes for adhe-
sion assay before plates were washed with phosphate-
buffered saline (PBSx1); attached cells were fixed with
3.7% formaldehyde and stained with crystal violet. Photo-
graphic images were acquired with Olympus SC20-CCD
on a bright-field microscopy. Cells that exhibited flatten-
ing and the presence of lamellipodia under microscope
examination were scored as spreading cells. Cell area was
assessed by Image J1.32 software (National Institutes of
Health).
Leucine uptake
[14C]- Leucine (50 μCi) was purchased from Perkin
Elmer, normal L-leucine from Sigma. 2× 105 lowCD98hc/-
or highC98hc/Caki2 cells were washed tree times in a Na-
free Solution (125 mM Cholin Cl, 4,8 mM KCl, 1,3 mM
CaCl2, 1,2 mM MgSO4, 25 mM Hepes-Tris, 1,2 mM
KH2PO4, 5,6 mM Glucose, pH 7,4) than 20 mM L-
Leucine/[14C]- Leucine was added to Na- free solution
for 1 min or 10 min, washed with Na free Uptake solution
and lysed with 50 μl RIPA-Buffer. After transferring ly-
sates in scintillation plates, 100 μl scintillator-liquid was
added and [14C] - Leucine uptake was measured via a
scintillator.
In vivo transplant assay
HighCD98hc/Caki2, lowCD98hc/Caki2, silC98hc/Caki2,
poinsilCD98hc/Caki2 and trunsilCD98hc/Caki2 cells were
xenotransplanted into 8 weeks old nude mice by subcuta-
neous injection (s.c.) into the right flank, five animals per
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extracted and embedded in mounting medium. 4 microm-
eter sections were stained immunohistochemically for
4'-6-diamidino-2-phenylindole (DAPI), CD98hc (C-20):
sc- 7095 (Santa Cruz Biotechnology, CA) or PCNA
(Abcam, UK).
Patients
The study included 51 paraffin-embedded ccRCCs, from
kidney origin. All tumors were derived from a well charac-
terized tissue bank of the Department of Clinical Pathology,
Medical University of Vienna. Specimens were sliced be-
fore they were routinely fixed overnight with 4.5% buf-
fered formaldehyde and stained for CD98hc as described
previously [6]. ccRCCs were classified according to the
TNM-System (T = Tumor, N =Node, M =Metastases ac-
cording to the Unio Internationalis Contra Cancrum,
UICC) [27], and graded according to Fuhrman et al. [28].
None of the patients had been treated with chemotherapy,
tyrosine kinase inhibitors or immunotherapy prior to
surgery.
Detailed information about Material and Methods is
located within Additional file 1.
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